Aspira Women's Health Inc. (AWHL): Total Assets
$5.46M
As of 2025-12-31
$4.43M
As of 2026-06-30
-32.0%
3-year compound annual growth
-22.6%
5-year compound annual growth
-12.6%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.46M | -0.6% | 2026-04-01, Balance as of period end |
| 2024-12-31 | $5.49M | -12.3% | 2026-04-01, Balance as of period end |
| 2023-12-31 | $6.26M | -64.0% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $17.37M | n/a | 2024-04-01, Balance as of period end |
| 2022-09-30 | $23.94M | n/a | 2023-10-26, Balance as of period end |
| 2021-12-31 | $41.08M | +109.5% | 2023-10-26, Balance as of period end |
| 2020-12-31 | $19.61M | +41.8% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $13.83M | +21.2% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $11.41M | +52.2% | 2020-04-07, Balance as of period end |
| 2017-12-31 | $7.50M | -6.5% | 2019-03-28, Balance as of period end |
| 2016-12-31 | $8.02M | -61.7% | 2018-03-13, Balance as of period end |
| 2015-12-31 | $20.96M | -13.3% | 2017-03-31, Balance as of period end |
| 2014-12-31 | $24.17M | -21.1% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $30.64M | +254.9% | 2015-03-31, Balance as of period end |
| 2012-12-31 | $8.63M | -62.6% | 2014-03-31, Balance as of period end |
| 2011-12-31 | $23.11M | -3.8% | 2013-03-01, Balance as of period end |
| 2010-12-31 | $24.04M | n/a | 2012-03-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $5.46M | -0.6% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $30.24M | +59.8% |
| Biomerica Inc (BMRA) | 2026-05-31 | $6.76M | +13.7% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $25.76M | -26.6% |
| Immucell Corp (ICCC) | 2025-12-31 | $42.53M | -5.7% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $103.58M | -12.8% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $6.90M | -26.6% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $582.98M | -26.4% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $842.13M | -29.3% |
Compare AWHL, NNNN, BMRA, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗